Total Payments
$87,677
2024 Payments
$49,169
Companies
24
Transactions
276
Medicare Patients
12,902
Medicare Billing
$9.2M
Payment Breakdown by Category
Other$40,592 (46.3%)
Consulting$25,175 (28.7%)
Food & Beverage$15,498 (17.7%)
Travel$6,324 (7.2%)
Education$87.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,892 | 11 | 42.1% |
| Consulting Fee | $25,175 | 8 | 28.7% |
| Food and Beverage | $15,498 | 237 | 17.7% |
| Travel and Lodging | $6,324 | 18 | 7.2% |
| Honoraria | $3,700 | 1 | 4.2% |
| Education | $87.92 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | $42,586 | 40 | $0 (2024) |
| Genentech USA, Inc. | $15,850 | 47 | $0 (2024) |
| Astellas Pharma US Inc | $11,155 | 14 | $0 (2024) |
| Alimera Sciences, Inc. | $6,544 | 34 | $0 (2024) |
| Alcon Vision LLC | $3,090 | 26 | $0 (2024) |
| Genentech, Inc. | $2,501 | 3 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $1,815 | 39 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,016 | 21 | $0 (2022) |
| Allergan, Inc. | $662.04 | 18 | $0 (2021) |
| ABBVIE INC. | $594.27 | 11 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,169 | 74 | Apellis Pharmaceuticals, Inc. ($33,564) |
| 2023 | $19,722 | 49 | Apellis Pharmaceuticals, Inc. ($7,032) |
| 2022 | $4,424 | 41 | Apellis Pharmaceuticals, Inc. ($1,990) |
| 2021 | $2,632 | 43 | Alcon Vision LLC ($847.23) |
| 2020 | $1,330 | 24 | Alcon Vision LLC ($860.10) |
| 2019 | $8,952 | 32 | Genentech USA, Inc. ($7,410) |
| 2018 | $1,150 | 9 | Alimera Sciences, Inc. ($460.16) |
| 2017 | $297.69 | 4 | Regeneron Healthcare Solutions, Inc. ($183.99) |
All Payment Transactions
276 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $284.89 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $269.95 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $116.42 | General |
| Category: Ophthalmology | ||||||
| 11/22/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,646.00 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Food and Beverage | In-kind items and services | $224.94 | General |
| Category: Ophthalmology | ||||||
| 11/16/2024 | Alcon Vision LLC | — | Travel and Lodging | In-kind items and services | $192.61 | General |
| Category: Ophthalmology | ||||||
| 11/15/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $30.99 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Ophthalmology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $922.18 | General |
| Category: Ophthalmology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Ophthalmology | ||||||
| 10/25/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $33.80 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $32.72 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Ophthalmology | ||||||
| 10/09/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,938.00 | General |
| Category: Ophthalmology | ||||||
| 10/09/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | Cash or cash equivalent | $138.82 | General |
| Category: Ophthalmology | ||||||
| 10/09/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $25.34 | General |
| Category: Ophthalmology | ||||||
| 09/25/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,646.00 | General |
| Category: Ophthalmology | ||||||
| 09/19/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/17/2024 | Astellas Pharma US Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| 09/13/2024 | Genentech USA, Inc. | Susvimo (Drug) | Food and Beverage | In-kind items and services | $27.98 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/13/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $7.09 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/12/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $631.95 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 3,238 | 48,606 | $12.3M | $2.9M |
| 2022 | 22 | 3,746 | 17,071 | $11.9M | $2.7M |
| 2021 | 20 | 3,358 | 10,400 | $9.0M | $2.1M |
| 2020 | 17 | 2,560 | 6,938 | $5.7M | $1.5M |
Total Patients
12,902
Total Services
83,015
Medicare Billing
$9.2M
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 131 | 39,480 | $4.2M | $1.1M | 27.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 159 | 1,540 | $3.2M | $1.1M | 32.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 60 | 1,306 | $1.4M | $235,871 | 16.7% |
| 67028 | Injection of drug into eye | Office | 2023 | 389 | 1,664 | $2.4M | $155,196 | 6.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 759 | 1,042 | $265,710 | $91,515 | 34.4% |
| 92134 | Imaging of retina | Office | 2023 | 1,085 | 2,747 | $354,363 | $82,792 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 255 | 255 | $102,000 | $30,260 | 29.7% |
| J3490 | Unclassified drugs | Office | 2023 | 11 | 17 | $58,450 | $29,977 | 51.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 192 | 262 | $45,850 | $17,466 | 38.1% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 12 | 12 | $60,696 | $9,446 | 15.6% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 15 | 15 | $71,442 | $8,969 | 12.6% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 50 | 129 | $38,700 | $6,630 | 17.1% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 22 | 26 | $52,380 | $4,519 | 8.6% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 19 | 19 | $5,415 | $1,722 | 31.8% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 31 | 34 | $12,274 | $1,011 | 8.2% |
| 92250 | Photography of the retina | Office | 2023 | 29 | 38 | $7,600 | $894.37 | 11.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 19 | 20 | $2,220 | $371.59 | 16.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 198 | 1,711 | $3.6M | $1.2M | 34.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 171 | 3,216 | $3.5M | $710,823 | 20.4% |
| J3590 | Unclassified biologics | Office | 2022 | 38 | 94 | $605,266 | $169,773 | 28.0% |
| 67028 | Injection of drug into eye | Office | 2022 | 435 | 1,734 | $2.4M | $160,086 | 6.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 39 | 4,980 | $534,404 | $148,610 | 27.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 828 | 1,141 | $290,955 | $98,989 | 34.0% |
| 92134 | Imaging of retina | Office | 2022 | 1,084 | 2,795 | $360,555 | $84,366 | 23.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 295 | 295 | $118,000 | $35,642 | 30.2% |
About Dr. Gregory Lee, M.D
Dr. Gregory Lee, M.D is a Retina Specialist healthcare provider based in Cumming, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2011. The National Provider Identifier (NPI) number assigned to this provider is 1609162155.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Lee, M.D has received a total of $87,677 in payments from pharmaceutical and medical device companies, with $49,169 received in 2024. These payments were reported across 276 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($36,892).
As a Medicare-enrolled provider, Lee has provided services to 12,902 Medicare beneficiaries, totaling 83,015 services with total Medicare billing of $9.2M. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Retina Specialist, Ophthalmology
- Location Cumming, GA
- Active Since 06/23/2011
- Last Updated 04/29/2024
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1609162155
Products in Payments
- Syfovre (Drug) $34,146
- Izervay (Drug) $9,832
- Lucentis (Biological) $7,975
- ILUVIEN (Drug) $5,304
- Susvimo (Drug) $5,150
- Vabysmo (Drug) $4,542
- EYLEA (Biological) $1,710
- OZURDEX (Drug) $1,113
- Constellation (Device) $1,095
- NGENUITY (Device) $1,062
- YUTIQ (Drug) $746.08
- BEOVU (Drug) $682.83
- VABYSMO (Drug) $371.31
- DAILIES (Device) $335.95
- EVA Ophthalmic Surgical System (Device) $331.68
- SUSVIMO (Drug) $241.41
- EYLEA AFLIBERCEPT INJECTION (Biological) $183.99
- Luxor (Device) $178.90
- EYLEA HD (Biological) $176.78
- XIPERE (Drug) $172.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.